|
|
||||||||
J Thorac Cardiovasc Surg 2004;127:1416-1420
© 2004 The American Association for Thoracic Surgery
Surgery for acquired cardiovascular disease |
a Division of Thoracic and Cardiovascular Surgery, Hannover Medical School, Hannover, Germany
Received for publication June 15, 2003; revisions received July 30, 2003; accepted for publication August 21, 2003.
* Address for reprints: Rainer G. Leyh, MD, PhD, Division of Thoracic and Cardiovascular Surgery, Hannover Medical School, Carl Neuberg St. 1, 30623 Hannover, Germany
leyh{at}thg.mh-hannover.de
| Abstract |
|---|
|
|
|---|
METHODS: From 1991 through 2001, 29 patients with prosthetic aortic valve endocarditis combined with aortic root destruction underwent reoperation at our institution. Sixteen patients received aortic root replacement with a cryopreserved aortic root allograft (group A) and 13 with a prosthetic composite graft (group B). The interval between the initial operation and reoperation was 29 months (range, 5-168 months) in group A and 55 months (range, 7-248 months) in group B.
RESULTS: Hospital mortality was 18.5% (n = 5 patients, 3 in group A and 2 in group B). Median follow-up was 21 months (range, 1-48 months) for group A and 34 months (range, 1-152 months) for group B (P > .2). Survival at 1 and 5 years was 81% ± 10% and 81% ± 10% in group A and 85% ± 10% and 85% ± 10% in group B, respectively. No patient underwent reoperation for recurrent prosthetic aortic valve endocarditis.
CONCLUSIONS: Our results indicate that excellent long-term results can be achieved regardless of the material used for aortic root replacement in patients with prosthetic aortic valve endocarditis.
In this retrospective study we reviewed the clinical data and outcomes for 29 patients who underwent reoperation for PVE associated with infectious destruction of the aortic root with homograft or composite aortic root replacement from 1991 through 2001 to elucidate whether the material used for aortic root replacement in PVE has any influence on short-term and long-term outcome.
| Material and methods |
|---|
|
|
|---|
|
Detected infectious microorganisms causing PVE
PVE was caused mainly by Staphylococcus aureus (n = 12 [41%]), and in 6 (21%) patients the infectious microorganism could not be detected (Table 2).
|
In addition, the sewing ring of the prosthesis was irrigated with a mixture of fibrin glue and gentamicin before implantation. In 12 (41%) patients additional surgical procedures were performed, as depicted in Table 3.
|
Statistical analysis
Data are expressed as medians with ranges or as the mean ± SD where appropriate. Demographic and baseline variables were analyzed by using the Student t test for continuous variables and the Fisher exact test for qualitative variables. Analysis of survival was performed by using the Kaplan-Meier method. Statistical differences in Kaplan-Meier survival estimates were determined by using the log-rank test. Statistical analyses were performed by using the SPSS for Windows software package (SPSS Inc).
| Results |
|---|
|
|
|---|
|
|
| Discussion |
|---|
|
|
|---|
The surgical goal in the treatment of PVE combined with infectious destruction of the aortic root is a low rate of recurrent PVE. It has been argued that the use of homograft material as a valve substitute in the setting of PVE with infectious destruction of the aortic root is associated with a lower mortality and a lower incidence of recurrent PVE compared with prosthetic material.9-11 We were not able to detect any differences regarding hospital mortality between the groups (group A, 18.7%; group B, 15.4%; P > .2). The overall mortality in our study cohort of 18.7% is comparable with what other investigators have previously reported. In the most recent studies, hospital mortality for PVE varied between 9.4% and 32%.2-4,8-10 Moreover, a meta-analysis from the United Kingdom heart valve registry showed a similar mortality rate averaging 20%.18 The second important issue in the treatment of PVE beside mortality is the incidence of recurrent PVE. Delay and coworkers19 demonstrated that surgical intervention for PVE can be performed with no hospital deaths; however, in this study freedom from reoperation was only 45% after 1 year.
We speculate that this might be the result of an intraoperative eradication failure of the underlying organism from the aortic root. In our patient population we had no recurrent PVE with a total follow-up of 47 ± 44 months (range, 1-152 months). Lytle and associates9 showed a recurrent rate of 3.8% within 1 year after surgical intervention for PVE by using homograft aortic root replacement as the second procedure. Hagl and colleagues10 demonstrated, with an almost identical patient cohort, a 4% recurrence rate for PVE after using prosthetic composite graft replacement for the treatment of PVE. In both series the entire aortic root was replaced either with homografts or prosthetic material. These findings might support the strategy of using aggressive surgical intervention to replace the aortic root in patients presenting with PVE. Data comparing the effect of biologic (homograft-autograft) material or prosthetic material on outcome in patients with PVE and infectious aortic root replacement are rare. Haydock and coworkers,11 as well as and McGiffin and associates,12 underlined the advantage of homograft aortic root replacement for PVE associated with annular destruction in a comparative study comparing homograft versus prosthetic aortic replacement for PVE. However, none of these studies were randomized, and the number of patients involved was limited. Recent published studies dealing with the problem of PVE and infectious destruction of the aortic root showed excellent short-term and long-term results: one group used homograft material, and the other group used prosthetic material for aortic root replacement in the presence of PVE.9,10 The results from these studies did not differ in terms of short- and long-term survival or in the incidence of recurrent PVE. From these studies and our own results, we believe that other factors in addition to the material used for the treatment of PVE might influence the outcome. Delahaye and associates20 showed that undue delay of operation for endocarditis is common and that the delay in surgical treatment might result in more severe infectious destruction of cardiac structures, with all resulting consequences. Furthermore, a more aggressive surgical approach to the treatment of PVE seems to influence the outcome.10,21 Hagl and associates10 stressed that patients presenting with PVE combined with infection beyond the valve annulus are best treated with aortic root replacement rather than aortic valve replacement and repair of annular destruction because of decreased hospital mortality after aortic root replacement. In our opinion a radical surgical approach with resection of all infectious and necrotic tissue regardless of the cardiac structures involved followed by complete aortic root replacement might be the clue to success in the treatment for PVE with infectious destruction of the aortic root.
Limitations
We wish to address several limitations. First, the number of patients in each group is too small to draw definite conclusions concerning the material that should be used in PVE with infectious destruction of the aortic root. However, in the most recent publications, the patient cohort with complicated PVE was almost similar to ours.6,9,10 Second, patients were not prospectively randomized, and the selection for either homograft or prosthetic aortic root replacement was dependent on the surgeon's preference only. Furthermore, the severity of the infection and the causative microorganism might vary between different patient cohorts.
Conclusions
Keeping all the aforementioned drawbacks of this study in mind, we believe that the material used for aortic root replacement in PVE with infectious destruction of the aortic root has no major effect on postoperative outcome. The strategy of early reoperation for PVE, thorough debridement, aggressive surgical technique, and prolonged antibiotic treatment might reduce mortality and the incidence of early and late recurrent PVE and improve long-term survival.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
2006 WRITING COMMITTEE MEMBERS, R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, et al. 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons Circulation, October 7, 2008; 118(15): e523 - e661. [Full Text] [PDF] |
||||
![]() |
R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al. 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons J. Am. Coll. Cardiol., September 23, 2008; 52(13): e1 - e142. [Full Text] [PDF] |
||||
![]() |
A. Saito, N. Motomura, K. Kakimi, K. Narui, N. Noguchi, M. Sasatsu, K. Kubo, Y. Koezuka, D. Takai, S. Ueha, et al. Vascular allografts are resistant to methicillin-resistant Staphylococcus aureus through indoleamine 2,3-dioxygenase in a murine model J. Thorac. Cardiovasc. Surg., July 1, 2008; 136(1): 159 - 167. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Okada, H. Tanaka, H. Takahashi, N. Morimoto, H. Munakata, M. Asano, M. Matsumori, Y. Kawanishi, K. Nakagiri, and Y. Okita Aortic Root Replacement for Destructive Aortic Valve Endocarditis with Left Ventricular-Aortic Discontinuity Ann. Thorac. Surg., March 1, 2008; 85(3): 940 - 945. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Lopes, P. Calvinho, F. de Oliveira, and M. Antunes Allograft aortic root replacement in complex prosthetic endocarditis Eur. J. Cardiothorac. Surg., July 1, 2007; 32(1): 126 - 130. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Mestres and J. M. Miro Editorial comment: Allograft aortic root replacement in complex prosthetic valve endocarditis Eur. J. Cardiothorac. Surg., July 1, 2007; 32(1): 131 - 132. [Full Text] [PDF] |
||||
![]() |
R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al. ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons J. Am. Coll. Cardiol., August 1, 2006; 48(3): e1 - e148. [Full Text] [PDF] |
||||
![]() |
Aortic root replacement after previous surgical intervention on the aortic valve, aortic root, or ascending aorta. J. Thorac. Cardiovasc. Surg., March 1, 2006; 131(3): 601 - 608. |
||||
![]() |
B. Mahesh, G. Angelini, M. Caputo, X. Y. Jin, and A. Bryan Prosthetic Valve Endocarditis Ann. Thorac. Surg., September 1, 2005; 80(3): 1151 - 1158. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Nottin, N. Al-Attar, R. Ramadan, A. Azmoun, A. Therasse, C. Kortas, M. Ly, A. Bouchachi, and M.-L. Bourachot-Montanteme Aortic Valve Translocation for Severe Prosthetic Valve Endocarditis: Early Results and Long-Term Follow-Up Ann. Thorac. Surg., May 1, 2005; 79(5): 1486 - 1490. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |